Regeneron agrees to settle licensing wrangle; Accuri raises $13M;

> Regeneron Pharmaceuticals has agreed to fork over $12.45 million to settle a licensing dispute with France's Cellectis. Report

> Accuri Cytometers has wrapped a $13 million Series C financing led by Fidelity Biosciences and Flagship Ventures. Accuri release

> The Washington Business Journal notes that aside from the resignation of MedImmune CEO David Mott, two other top executives decamped in June. Report

> Nicholas Stergis, co-founder of Pipex Pharmaceuticals and vice chairman of the board of directors, has been named CEO, replacing Steve H. Kanzer who will continue to serve as Pipex's chairman. Release

> Giaconda Limited has suspended its Phase IIa trial of Hepaconda for Hepatitis C in people with "genotype 1" infection. Significant improvement was demonstrated in liver function among participants in the study, says Giaconda, but "total normalization was not achieved and further formulation is warranted before continuing the study." Giaconda release

> The FDA has approved Bayer's contrast agent Primovist for identifying liver lesions. Report 

> Like its Big Pharma brethren, Bayer is casting a gimlet eye on the drug market in China. The company says it's aiming for 20 percent-plus annual growth in China for each of the next five years. Report

> Yesterday's recommendation that kids as young as 8 years old should take statins to prevent future heart problems--made by the prestigious and influential American Academy of Pediatrics--may have seemed tailor-made for a new indication for some of these drugs. But it triggered a furious backlash. Report

> Pricey cancer meds aren't just putting the squeeze on patients and insurers. They're putting oncologists in a financial quandary as well. Report

> When it comes to diversifying through generics, count GlaxoSmithKline out. CEO Andrew Witty says he has no interest in duking it out in that marketplace. Report

And Finally... Animal rights activists are taking their fight to the streets--targeting the homes of scientists involved in biomedical research. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.